A significant decrease in cholesterol, triglycerides, total lipids, SGOT, SGPT, and glucose was found in the NAFLD groups treated with MO infusion and in ethanolic extract compared to the NAFLD-placebo group (p=0.001). This evidence concerns the gene GPT and metabolic dysfunction-associated steatotic liver disease.